1. Tackling Schizophrenia With Your Patients

3. This program may include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Prevalence of Schizophrenia

5. Schizophrenia Symptoms

6. Schizophrenia Time Course

7. Relationship Between Negative Symptoms, Cognitive Deficits, and Function

8. Treatment-Related Adverse Effects and QoL

9. Treatment-Resistant Schizophrenia

10. Trace Amine-Associated Receptor 1

11. Clinical Trials of Cariprazine in Schizophrenia

12. Phase 2 Trial of RP5063 in Schizophrenia or Schizoaffective Disorder

13. Phase 2b Trial of MIN-101 in Stable Schizophrenia With Negative Symptoms

14. Lumateperone: A First-in-Class Novel Agent for Schizophrenia

15. Clinical Trials of Lumateperone in Schizophrenia

16. What Is an Adequate Trial of an Antipsychotic?

17. Rating Scales in Schizophrenia

18. Patient Self-Report

19. Key Drivers of Nonadherence to Antipsychotic Therapy in Schizophrenia

20. Monitoring Antipsychotic Plasma Levels

21. Role for Predictive Biomarkers in Schizophrenia

22. NIMH RAISE Early Treatment Program

23. Conclusions

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)